Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
- Type: Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 8
- Moderators:L. Crinò
- Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
-
+
OA03.07 - KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab
12:05 - 12:15 | Author(s): R. Herbst
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA07 - ALK-ROS1 in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:N. Singh
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 1-2
-
+
MA07.01 - Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC
11:00 - 11:06 | Author(s): S. Ignatius Ou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA07.02 - Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
11:06 - 11:12 | Author(s): D..R. Camidge
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA08 - Treatment Monitoring in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:R. Perez-Soler
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 3-4
-
+
MA08.01 - A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
11:00 - 11:06 | Author(s): H. Wakelee
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA09 - Immunotherapy Combinations
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:M. Sebastian
- Coordinates: 12/06/2016, 14:20 - 15:50, Strauss 2
-
+
MA09.02 - Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G
14:26 - 14:32 | Author(s): C. Langer
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.06 - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
- Presentations: 47
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.06-014 - Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy
14:30 - 14:30 | Author(s): J. Nemunaitis
- Abstract
Loading...
-
+
PL04a - Plenary Session: Immune Checkpoint Inhibitors in Advanced NSCLC
- Type: Plenary
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 5
- Moderators:J. Soria
- Coordinates: 12/07/2016, 08:45 - 09:40, Hall D (Plenary Hall)
-
+
PL04a.02 - OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses (Abstract under Embargo until December 7, 7:00 CET)
08:55 - 09:05 | Author(s): S.M. Gadgeel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
PR04 - Press Conference: Advanced Care
- Type: Press Conference
- Track:
- Presentations: 5
- Moderators:C. Zielinski
- Coordinates: 12/07/2016, 10:30 - 11:45, Schubert 1
-
+
PR04.02 - OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses
10:30 - 10:30 | Author(s): S.M. Gadgeel
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA23 - EGFR Targeted Therapies in Advanced NSCLC
- Type: Oral Session
- Track: Advanced NSCLC
- Presentations: 8
- Moderators:O.T. Brustugun
- Coordinates: 12/07/2016, 14:20 - 15:50, Stolz 2
-
+
OA23.03 - Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial
14:40 - 14:50 | Author(s): G. Goss
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.02a - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 37
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-016 - Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)
14:30 - 14:30 | Author(s): J.C. Yang
- Abstract
Loading...
-
+
P3.02b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 126
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-003 - Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumour and Serum Biomarkers
14:30 - 14:30 | Author(s): E. Felip
- Abstract
Loading... -
+
P3.02b-103 - Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing
14:30 - 14:30 | Author(s): J.J. Lin
- Abstract
Loading... -
+
P3.02b-115 - Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
14:30 - 14:30 | Author(s): S.M. Gadgeel
- Abstract
Loading...